SCHEMBL4142873

SCHEMBL4142873

O=C(N[C@H]1CCCN(c2ccccc2)C1)C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.54
ALDH1A1 P00352 3/20 0.51
LMNA P02545 1/20 0.51
KMT2A Q03164 2/20 0.48
RAB9A P51151 1/20 0.48
EPHX1 P07099 2/20 0.46
P2RX7 Q99572 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
DRD2 P14416 2/20 0.44
DRD3 P35462 2/20 0.44
HSD11B1 P28845 1/20 0.43
CNR2 P34972 1/20 0.43
POLB P06746 1/20 0.42
HTR2A P28223 1/20 0.42
NOTUM Q6P988 1/20 0.42
MEN1 O00255 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4148781 0.91 CNR1 (0.48) CNR1ALDH1A1LMNAKMT2ARAB9A
SCHEMBL4137890 0.89 SMN1; SMN2 (0.53) CNR1ALDH1A1LMNAKMT2ARAB9A
SCHEMBL4005560 0.80 CNR1 (0.38) CNR1ALDH1A1KMT2ARAB9AEPHX1
SCHEMBL5950362 0.80 CNR1 (0.38) CNR1ALDH1A1KMT2ARAB9AEPHX1
SCHEMBL27707859 0.80 CNR1 (0.38) CNR1ALDH1A1KMT2ARAB9AEPHX1
SCHEMBL4010313 0.80 CNR1 (0.47) CNR1ALDH1A1LMNAKMT2ARAB9A
SCHEMBL4011282 0.80 CNR1 (0.64) CNR1ALDH1A1SMN1; SMN2DRD2DRD3
SCHEMBL14859926 0.80 CNR1 (0.64) CNR1ALDH1A1SMN1; SMN2DRD2DRD3
SCHEMBL4011287 0.80 CNR1 (0.64) CNR1ALDH1A1SMN1; SMN2DRD2DRD3
SCHEMBL4795963 0.79 ALDH1A1 (0.48) CNR1ALDH1A1LMNAKMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1778229-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2009-06-17 EP claimed
EP-1778229-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-05-02 EP claimed
US-20060122197-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-08 US claimed
WO-2006020598-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-23 WO claimed
EP-1778229-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2009-06-17 EP disclosed
EP-1778229-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-05-02 EP disclosed
US-20060122197-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-08 US disclosed
WO-2006020598-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122197-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 CNR1 516/4885ALDH1A1 311/4885LMNA 2149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.